Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Transplant Cell Ther. 2021 Nov 12;28(2):83.e1–83.e9. doi: 10.1016/j.jtct.2021.10.022

Figure 1:

Figure 1:

Unadjusted progression free survival and overall survival in patients receiving VRD (N=914, 80.5%) vs VCD (N=221, 19.5%) induction therapy for newly diagnosed multiple myeloma.